Management and outcomes of patients with renal medullary carcinoma (RMC): A collaborative multi-center study of 52 patients.
Amishi Y. Shah(The University of Texas MD Anderson Cancer Center), Nizar M. Tannir(The University of Texas MD Anderson Cancer Center), Christopher G. Wood(Massachusetts Eye and Ear Infirmary), Elizabeth R. Plimack(Fox Chase Cancer Center), Kanishka Sircar(McGill University), Priya Rao(The University of Texas MD Anderson Cancer Center), Gabriel G. Malouf(Centre National de la Recherche Scientifique), Lianchun Xiao(The University of Texas MD Anderson Cancer Center), Jianjun Gao(Chinese General Hospital College of Nursing and Liberal Arts), José A. Karam(The University of Texas MD Anderson Cancer Center), Ulka N. Vaishampayan(University of Michigan), Chunkit Fung(Oslo University Hospital), W. Kimryn Rathmell(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Surena F. Matin(The University of Texas MD Anderson Cancer Center), Elizabeth A. Guancial(Harvard University), Pheroze Tamboli(The University of Texas MD Anderson Cancer Center), Zita Dubauskas Lim(The University of Texas MD Anderson Cancer Center), Eric Jonasch(The University of Texas MD Anderson Cancer Center), Daniel Yick Chin Heng(University of Calgary), Stefanie Lowas(Monroe Carell Jr. Children's Hospital)
Cited by 0
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k